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Innovations
Thios Pharmaceuticals
Targeting Sulfation Pathways
transplant. “These represent serious disease. There are more than 500
kinases, but far fewer sulfotransfer-unmet medical needs for which
ases are found in the human ge-there are currently no effective ther-
Appropriately named by using the
Greek word for the element sulfur,
Thios Pharmaceuticals is a 3-year-
old, 24-person company based in nome, about 50. Says Dr.Bertozzi,apies,” says Mr. Hironaka. In addition,
Emeryville, California, focused on “Among the kinases, there are someThios has a therapeutic antibody pro-
one of the body’s major regulatory clean kinases upregulated only ingram targeting sulfoadhesin, a sul-
mechanisms: sulfation. cancers, and there are messier ki-fated polysaccharide contributing to
This process involves the addi- nases with functions in normal phys-chronic inflammation.
tion (or removal) of sulfate groups to iology. If you hit those latter kinases,Thios’ small molecule drug devel-
important glycoproteins, a modifica- toxic side effects become a prob-opment programs revolve around
tion that can modulate interactions lem. The same will be true of somesulfation enzymes. “Our goal over
at the cell surface and in the extra- of the sulfotransferases and the sul-the long term is to develop small
cellular space. If one or more of the fatases, so we are being very strate-molecule modulators of the sulfo-
key components of sulfation path- gic about our target selection.”transferase and sulfatase enzymes
ways becomes dysregulated, sev- Thios is honing in on druggablethat are involved in sulfation biology
eral biological processes like cell “clean” sulfotransferase and sul-which have the greatest therapeutic
adhesion, cell migration, immune re- fatase targets that are upregulatedvalue,” says Stephen Harrison, PhD,
sponses, and cell proliferation may only in disease tissue. “Fifty targetsVice President of Research at Thios.
be inappropriately regulated, lead- are enough so that there are plenty
ing to specific diseases such as in- to work on from the point of view of
flammation and cancer. drug discovery, but not so over-
Our mission is to discover,Productive Pathways whelming a number that selectivity
problems arise,” says Dr. Bertozzi.for Drug Discovery develop, and commer-
“Our mission is to discover, develop, The company is hoping sulfation in-cialize innovative thera-and commercialize innovative thera- hibition will echo the commercial
pies targeting biologicalpies targeting biological sulfation to success of kinase inhibitors, such as
the cancer therapy, Gleevec. Gleevectreat serious unmet medical needs,” sulfation to treat serious
says Bruce A. Hironaka, President was FDA approved in 2001 for treat-unmet medical needs.”and CEO of Thios. “Simply, we want ment of chronic myeloid leukemia
–Bruce A. Hironaka, Presi-to be the leader in the development and in 2003 generated sales of over
$1.1 billion.of this new class of therapies and to dent and CEO, Thios Phar-
improve the lives of many through Sulfation Science Is Fairly Newmaceuticalsthe development of safer, more ef- “The field of biological sulfation has
fective therapies.” developed only recently,” says Dr.
To achieve this, Thios is focusing Bertozzi. “The pharmaceutical rele-
Analogies to Kinaseson two types of programs. “Our ma- vance was brought to light only in
“The big picture here is that sulfationjor emphasis is in small-molecule the late 1990s due to a handful of
is a regulatory modification of bio-drug discovery, and we also have a discoveries linking sulfation with in-
polymers and even small mole-therapeutic antibody program,” ac- flammatory disease and, more re-
cules,” says Dr. Bertozzi. She drawscording to Carolyn Bertozzi, PhD, cently, correlations between sulfo-
an analogy between sulfation of bio-Professor, Chemistry and Molecular transferase or sulfatase expression
molecules with protein phosphory-and Cell Biology, University of Cali- and cancer.”
lation. “Proteins are phosphorylatedfornia, Berkeley, and a Thios cofoun- Most of the founders of Thios
by kinases and dephosphorylatedder. The company currently focuses Pharmaceuticals spent time at one
by phosphatases. So the kinaseson three classes of sulfation targets: point in the lab of Steven Rosen,
and phosphatases serve a regula-sulfated molecules, sulfotransfer- PhD, at the University of California,
tory function in signaling cascades.”ases, and sulfatases. Thios is tar- San Francisco. Dr. Rosen has been
Likewise, sulfotransferases and sul-geting sulfated molecules as either studying leukocyte-endothelial cell
fatases regulate the sulfation of bio-therapeutics in their own right or adhesion, one of the first steps in
molecules controlling their ac-as targets for an antibody drug it the inflammatory cascade, since the
tivities.has under development. In January late 1980s. In late 2000, Dr. Bertozzi
Kinases have generated a lot of2004, Thios in-licensed a sulfated (a former post-doc in the Rosen lab)
interest because of their involvementglycoprotein called TS1 from Wyeth joined forces with Rosen, another
in a variety of regulatory events, manyfor acute sickle cell crisis and de- former Rosen post-doc, Stefan Hem-
merich, then working at Roche Bio-layed graft function after kidney related to cancer and proliferative
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sciences, and Ted Yednock at Elan rison. This is a mechanism that is not “We expect big pharma compa-
yet being approached by availablePharmaceuticals to form Thios. “We nies to have a growing interest in
anti-inflammatories. “In combina-realized sulfation wasn’t just impor- sulfation targets if they don’t al-
tion with other anti-inflammatorytant in inflammation, but there were ready,” suspects Dr. Bertozzi. Aside
agents, we have the theoretic poten-papers in the literature linking dys- from the Wyeth deal, other compa-
tial then to get synergistic activity,”regulated sulfation to viral infection nies have approached Thios with an
he says, though Thios is currentlyand cancer,” explains Dr. Bertozzi. interest in sulfation biotherapies.
focusing on single-agent therapy.“It became clear there was a whole “We are inevitably coming up with
Another of Thios’ anti-inflamma-niche of biology that could be mined additional targets that, given the re-
tory programs targets sulfoadhesinfor drug development.” sources we have, we’re not able to
via a different mechanism. Thios isInflammation move forward, which makes us an
pursuing small molecule inhibitorsInflammation is a primary indication ideal partner in this area,” adds Dr.
of the sulfotransferase that adds sul-for Thios. The TS1 biotherapeutic Harrison. Thios is interested in part-
fate to sulfoadhesin during its bio-molecule in-licensed from Wyeth nering with other companies, both
synthesis inside the cell. L-selectinhas been through two phase II trials large pharma and biotech, inter-
binding requires sulfation of the li-involving more than 500 patients but ested in accessing some of the
gand, thus inhibition of the sulfotrans-in a separate indication than those Thios’ targets or around programs
ferase would prevent leukocyte ad-Thios is pursuing. TS1, formerly with potential complementary ac-
hesion and the resulting pathologyrPSGL-Ig, is a sulfated recombinant tivities.
of inflammation. Thios believes thefusion protein based on P-selec-
Chemistry & Biology invites yoursmall molecule inhibitors of the sul-tin glycoprotein ligand 1 (PSGL-1).
comments on this topic. Pleasefotransferase have the potential toPSGL-1 extends from the surface of
write to the editors at chembiol@treat asthma, rheumatoid arthritis,leukocytes, helping cells bind to the
cell.com.psoriasis, and inflammatory bowelblood vessel wall both in normal tis-
disease.sue repair and after ischemia/reper- Alice A. McCarthy is a freelance science“The classes of sulfotransferasesfusion injury and vaso-occlusion. At- writer based in Gloucester, MA (alice@we are targeting in general residetachment of leukocytes to damaged alicemccarthy.com).
within the Golgi,” explains Harrison.blood vessels intensifies local in-
“But there are a number of sulfo-
flammation, causing further tissue
transferases we find in the cytosol
damage. TS1 protects the site of tis-
that are often involved in detoxifica-
sue damage by preventing leuko- tion and the metabolism of toxins
cytes and platelets from adhering within the body. Clearly, it would not
and causing inappropriate inflam- be a good idea to inhibit those.” As
mation and/or thrombosis. It may such, an essential element of Thios’
also have potential for other condi- screening funnel eliminates com-
tions like deep vein thrombosis and pounds that offer broad-based sul-
arterial vascular diseases, including fotransferase inhibition.
stroke. According to Mr. Hironaka, Bertozzi explains that the anti-
“The in-licensing of TS1 was part of body project is moving more quickly
our strategy to mature our product than the small molecule project. “We
candidate pipeline in the short term think we’ll be able to get IND filing
and to position us to be an early and our first clinical candidates in
stage development company early the antibody program in a reason-
on in our history.” Thios plans to re- able time frame,” she says. And if
enter the clinic with TS1 by year- that pans out, it will validate the sul-
end 2004. fotransferase inhibitor program. “The
The sulfoadhesin antibody anti- small molecule compound could be
inflammatory program is presently in the orally bioavailable pill, while the
preclinical development. Sulfoadhe- antibody would be an injectable.”
sin is found on the surface of endo- Cancer
thelial cells in the blood vessel wall “We’re looking at some particularly
at sites of chronic inflammation. interesting sulfatases with potential
Thios is working on developing a in the area of oncology,” says Dr.
therapeutic antibody that binds to Harrison. Thios has identified two
sulfoadhesin and prevents its asso- extracellular sulfatases as potential
ciation with L-selectin, a receptor on targets for the development of small
circulating white blood cells. “By molecule therapeutics that inhibit
blocking that ligand, we should be tumor growth. Its Sulf-1 sulfatase is
able to block leukocyte recruitment highly active in prostate and central
at the sites of inflammation and nervous system cancers, whereas
therefore block the inflammation its activity in normal tissues is much
even before the leukocytes have be- lower. Sulf-2 is present at very high
levels in breast cancer tissue.come activated,” explains Dr. Har-
